Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaav5989. doi: 10.1126/scitranslmed.aav5989.

PMID:
31189721
2.

Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing.

Ulrich P, Blaich G, Baumann A, Fagg R, Hey A, Kiessling A, Kronenberg S, Lindecrona RH, Mohl S, Richter WF, Tibbitts J, Crameri F, Weir L.

Regul Toxicol Pharmacol. 2018 Apr;94:91-100. doi: 10.1016/j.yrtph.2018.01.013. Epub 2018 Jan 28.

PMID:
29355662
3.

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P.

Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.

4.

Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new Insights.

Blaich G, Baumann A, Kronenberg S, de Haan L, Ulrich P, Richter WF, Tibbitts J, Chivers S, Tarcsa E, Caldwell R, Crameri F.

Regul Toxicol Pharmacol. 2016 Oct;80S:S1-S14. doi: 10.1016/j.yrtph.2016.08.012. Epub 2016 Aug 27.

PMID:
27578450
5.

Accreditation and reciprocal recognition.

Crameri FM.

Vet Pathol. 2010 Nov;47(6):1113. doi: 10.1177/0300985810374838. No abstract available.

PMID:
21041544
6.

Modulation of oral squamous cell carcinoma incidence in rats via diet and a novel calcium channel antagonist.

Lenz B, Crameri FM, Eichler DA, Schläppi B, Wiltshire HR, Wood J, Seymour RA.

Toxicol Pathol. 2005;33(3):356-64.

PMID:
15805073
7.

Modulation of gene and protein expression by carbon tetrachloride in the rat liver.

Fountoulakis M, de Vera MC, Crameri F, Boess F, Gasser R, Albertini S, Suter L.

Toxicol Appl Pharmacol. 2002 Aug 15;183(1):71-80.

PMID:
12217644
8.

Two-dimensional database of mouse liver proteins: changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol.

Fountoulakis M, Berndt P, Boelsterli UA, Crameri F, Winter M, Albertini S, Suter L.

Electrophoresis. 2000 Jun;21(11):2148-61.

PMID:
10892726
9.

Serum-free conditions for the long term growth and differentiation of neoplastic canine keratinocytes.

Crameri FM, Varvayanis M, Cromie BR, Rekers WL, Suter MM.

Exp Dermatol. 1997 Jun;6(3):147-55.

PMID:
9226138
10.
11.

Extracellular ATP and some of its analogs induce transient rises in cytosolic free calcium in individual canine keratinocytes.

Suter MM, Crameri FM, Slattery JP, Millard PJ, Gonzalez FA.

J Invest Dermatol. 1991 Aug;97(2):223-9.

12.

Two rare cutaneous neoplasms in horses: apocrine gland adenocarcinoma and carcinosarcoma.

Anderson WI, Scott DW, Crameri FM.

Cornell Vet. 1990 Oct;80(4):339-45.

13.

Primary vertebral hemangiosarcoma in a dog.

Parchman MB, Crameri FM.

J Am Vet Med Assoc. 1989 Jan 1;194(1):79-81.

PMID:
2914798
14.

[Misuse of thyrostatic drugs in cattle: determination of thyroxine (T4) concentration and thyroid weight and detection of methylthiouracil (MTU)].

Venzin I, Blum J, Crameri F, Ehrensperger F, Lutz H.

Schweiz Arch Tierheilkd. 1986 Sep;128(9):443-58. German. No abstract available.

PMID:
3775350

Supplemental Content

Loading ...
Support Center